225 related articles for article (PubMed ID: 31117178)
21. Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis.
Mathew V; Wang AK
Drug Des Devel Ther; 2019; 13():1515-1525. PubMed ID: 31118583
[TBL] [Abstract][Full Text] [Related]
22. Advances in the treatment of hereditary transthyretin amyloidosis: A review.
Gertz MA; Mauermann ML; Grogan M; Coelho T
Brain Behav; 2019 Sep; 9(9):e01371. PubMed ID: 31368669
[TBL] [Abstract][Full Text] [Related]
23. Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data.
Viney NJ; Guo S; Tai LJ; Baker BF; Aghajan M; Jung SW; Yu RZ; Booten S; Murray H; Machemer T; Burel S; Murray S; Buchele G; Tsimikas S; Schneider E; Geary RS; Benson MD; Monia BP
ESC Heart Fail; 2021 Feb; 8(1):652-661. PubMed ID: 33283485
[TBL] [Abstract][Full Text] [Related]
24. TTR gene silencing therapy in post liver transplant hereditary ATTR amyloidosis patients.
Moshe-Lilie O; Dimitrova D; Heitner SB; Brannagan TH; Zivkovic S; Hanna M; Masri A; Polydefkis M; Berk JL; Gertz MA; Karam C
Amyloid; 2020 Dec; 27(4):250-253. PubMed ID: 32578459
[TBL] [Abstract][Full Text] [Related]
25. Inotersen to Treat Polyneuropathy Associated with Hereditary Transthyretin (hATTR) Amyloidosis.
Robinson C; Pham C; Zamarripa AM; Dugay CS; Lee CA; Berger AA; Landman A; Cornett EM; Kassem H; Kaye AD; Urits I; Viswanath O; Ganti L
Health Psychol Res; 2022; 10(5):67910. PubMed ID: 36726478
[TBL] [Abstract][Full Text] [Related]
26. Long-term treatment effects of inotersen on health-related quality of life in patients with hATTR amyloidosis with polyneuropathy: Analysis of the open-label extension of the NEURO-TTR trial.
Karam C; Brown D; Yang M; Done N; Zhu JJ; Greatsinger A; Bozas A; Vera-Llonch M; Signorovitch J
Muscle Nerve; 2022 Oct; 66(4):438-446. PubMed ID: 35799473
[TBL] [Abstract][Full Text] [Related]
27. Focal Segmental Glomerulosclerosis Complicating Therapy With Inotersen, an Antisense Oligonucleotide Inhibitor: A Case Report.
Law S; Arnold J; Rauf MU; Heptinstall L; Gilbertson J; Rowczenio D; Baharani J; Langman G; Fontana M; Gillmore JD
Am J Kidney Dis; 2023 May; 81(5):606-610. PubMed ID: 36228827
[TBL] [Abstract][Full Text] [Related]
28. Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care.
Luigetti M; Romano A; Di Paolantonio A; Bisogni G; Sabatelli M
Ther Clin Risk Manag; 2020; 16():109-123. PubMed ID: 32110029
[TBL] [Abstract][Full Text] [Related]
29. The impact of inotersen on Neuropathy Impairment Score in patients with hereditary transthyretin amyloidosis with polyneuropathy.
Yarlas A; Lovley A; Brown D; Vera-Llonch M; Khella S; Karam C
BMC Neurol; 2023 Mar; 23(1):108. PubMed ID: 36932361
[TBL] [Abstract][Full Text] [Related]
30. Vutrisiran: First Approval.
Keam SJ
Drugs; 2022 Sep; 82(13):1419-1425. PubMed ID: 35997942
[TBL] [Abstract][Full Text] [Related]
31. Inotersen and severe thrombocytopenia: 2 case reports and review.
Domínguez Senín L; Borrachero Garro C; Sánchez Gómez E; Santos-Rubio MD
Int J Clin Pharmacol Ther; 2022 Jul; 60(7):311-316. PubMed ID: 35343431
[TBL] [Abstract][Full Text] [Related]
32. Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS + 7.
Dyck PJB; González-Duarte A; Obici L; Polydefkis M; Wiesman JF; Antonino I; Litchy WJ; Dyck PJ
J Neurol Sci; 2019 Oct; 405():116424. PubMed ID: 31445300
[TBL] [Abstract][Full Text] [Related]
33. Development and Clinical Applications of Antisense Oligonucleotide Gapmers.
Chan L; Yokota T
Methods Mol Biol; 2020; 2176():21-47. PubMed ID: 32865780
[TBL] [Abstract][Full Text] [Related]
34. Understanding the Disease Course and Therapeutic Benefit of Tafamidis Across Real-World Studies of Hereditary Transthyretin Amyloidosis with Polyneuropathy: A Proof of Concept for Integrative Data Analytic Approaches.
Serrano D; Atzinger CB; Botteman MF
Neurol Ther; 2018 Jun; 7(1):141-154. PubMed ID: 29611130
[TBL] [Abstract][Full Text] [Related]
35. A comparative analysis of international health technology assessments for novel gene silencing therapies: patisiran and inotersen.
Iannazzo S
Glob Reg Health Technol Assess; 2021; 8():14-21. PubMed ID: 36627862
[TBL] [Abstract][Full Text] [Related]
36. Hereditary ATTR Amyloidosis in Austria: Prevalence and Epidemiological Hot Spots.
Auer-Grumbach M; Rettl R; Ablasser K; Agis H; Beetz C; Duca F; Gattermeier M; Glaser F; Hacker M; Kain R; Kaufmann B; Kovacs GG; Lampl C; Ljevakovic N; Nagele J; Pölzl G; Quasthoff S; Raimann B; Rauschka H; Reiter C; Skrahina V; Schuhfried O; Sunder-Plassmann R; Verheyen ND; Wanschitz J; Weber T; Windhager R; Wurm R; Zimprich F; Löscher WN; Bonderman D
J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32674397
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity Assessment of Inotersen, a 2'-
Yu RZ; Wang Y; Norris DA; Kim TW; Narayanan P; Geary RS; Monia BP; Henry SP
Nucleic Acid Ther; 2020 Oct; 30(5):265-275. PubMed ID: 32833564
[TBL] [Abstract][Full Text] [Related]
38. Inotersen therapy of transthyretin amyloid cardiomyopathy.
Dasgupta NR; Rissing SM; Smith J; Jung J; Benson MD
Amyloid; 2020 Mar; 27(1):52-58. PubMed ID: 31713445
[No Abstract] [Full Text] [Related]
39. Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides.
Ackermann EJ; Guo S; Benson MD; Booten S; Freier S; Hughes SG; Kim TW; Jesse Kwoh T; Matson J; Norris D; Yu R; Watt A; Monia BP
Amyloid; 2016 Sep; 23(3):148-157. PubMed ID: 27355239
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
